Tax-driven stock sale by ALX Oncology (ALXO) CAO Shelly Pinto

Rhea-AI Filing Summary

ALX Oncology Holdings Inc. senior vice president and chief accounting officer Shelly Pinto reported an open-market sale of 565 shares of common stock at $2.27 per share. According to the disclosure, the shares were sold solely to cover tax obligations from vesting restricted stock units. After this transaction, Pinto holds 87,708 shares directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pinto Shelly

(Last) (First) (Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, FINANCE AND CAO

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		S(1)		565	D	$2.27	87,708	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

	/s/ Shelly Pinto	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ALXO executive Shelly Pinto report?

Shelly Pinto reported selling 565 ALX Oncology common shares. The sale was executed in the open market at $2.27 per share and was tied to covering tax obligations from vesting restricted stock units rather than a discretionary portfolio reallocation.

Why did ALXO SVP Shelly Pinto sell 565 shares of stock?

The 565 ALX Oncology shares were sold to satisfy Shelly Pinto’s tax obligations. The filing states the sale was directly connected to the vesting of restricted stock units, indicating a tax-related transaction rather than an independent decision to reduce her overall investment position.

What price did ALXO shares sell for in Shelly Pinto’s Form 4 filing?

The reported 565 ALX Oncology common shares sold at $2.27 each. This per-share price comes from a single open-market transaction and is disclosed directly in the insider report, providing transparency on the execution level for this small tax-related sale.

How many ALXO shares does Shelly Pinto own after the reported sale?

After the transaction, Shelly Pinto directly owns 87,708 ALX Oncology common shares. This post-transaction balance is disclosed in the filing and shows that the tax-related sale represented only a small fraction of her overall reported direct holdings in the company.

Is Shelly Pinto’s ALXO stock transaction categorized as a buy or sell?

The transaction is categorized as a sell in the insider report. It is coded as an open-market sale of common stock, though the footnote clarifies that the purpose was to satisfy tax obligations arising from the vesting of restricted stock units, not discretionary trading.